You could be right. Today's announcement quotes the Chief Executive Office Colin Sutton:
"We are satisfied with the performance of the VentrAssist in all patients who have participated in the Pilot trial being conducted at The Alfred hospital in Melbourne to test the safety of the device."
This could be construed to mean that there is no need to conduct further Australian trials.
If so, this stock is at an exciting stage.